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Abstract
Butyric acid and trichostatin A (TSA) are anti-cancer compounds that cause the upregulation of genes involved in
differentiation and cell cycle regulation by inhibiting histone deacetylase (HDAC) activity. In this study we have synthesized
and evaluated compounds that combine the bioavailability of short-chain fatty acids, like butyric acid, with the bidentate
binding ability of TSA. A series of analogs were made to examine the effects of chain length, simple aromatic cap groups, and
substituted hydroxamates on the compounds’ ability to inhibit rat-liver HDAC using a fluorometric assay. In keeping with
previous structure-activity relationships, the most effective inhibitors consisted of longer chains and hydroxamic acid groups.
It was found that 5-phenylvaleric hydroxamic acid and 4-benzoylbutyric hydroxamic acid were the most potent inhibitors with
IC50’s of 5mM and 133mM respectively.
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Introduction
Reversible modification of chromatin’s structure plays
a fundamental role in regulating gene transcription.
Histone acetyltranferases (HATs) and histone deace-
tylases (HDACs) are enzymes that work in tandem to
acetylate and deacetylate the e-amino groups on the
lysine residues located in the N-terminal region of the
core histone proteins [1–3]. Acetylation of these
residues by HATs neutralizes the histones’ positive
charge and decreases the DNA’s affinity for the
protein. The DNA then unwinds and allows the cell’s
transcriptional machinery access to the strand thereby
promoting gene expression. HDACs reverse this
process by cleaving the acetyl groups. This results in
a closed chromatin structure and the repression of
gene expression. Inhibition of HDAC activity
therefore has the effect of promoting the transcription
of silenced genes. Application of HDAC inhibitors in
cancer cell lines and mouse model systems leads to
interruption of the cell cycle, differentiation, and
apoptosis [3–6]. Clinical studies have shown tumor
repression and improvement of patient symptoms
without significant side effects. These therapeutic
effects are a result of increased expression of proteins
such as p21WAF1/CIP1, FAS, and caspase 3 [7–9].
Structure-activity relationship studies of various
HDAC enzymes and X-ray crystal structures of
inhibitors bound to a histone deacetylase-like protein
(HDLP) from Aquifex aeolicus have elucidated
HDACs’ conserved active site [10–12]. Hydrolysis
of the acetylated lysine residue is promoted by
coordination of the carbonyl oxygen with a Znþ2
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cation. The Znþ2 cation lies at the bottom of a
hydrophobic channel, greatly influencing the structure
of inhibitors. Although many classes of inhibitors have
been developed, they all have a Zn-binding moiety
located at the end of hydrophobic linker chain for
proper placement in this channel (Figure 1). Opposite
the Zn-binding group, most inhibitors incorporate a
hydrophobic cap structure that has been shown to
interact with aromatic residues at the mouth of the
channel. Consequently, many of these groups are
aromatic in nature, but can very greatly in size and
secondary functionality.
One of the first compounds found to inhibit HDAC
was sodium butyrate (Figure 1). It is representative of
the short-chain fatty acid class of inhibitors. A fatty
acid found naturally in the body, its biological effects
have been well studied [13,14]. Although a non-
specific, millimolar level inhibitor of HDAC, it has
been found to induce differentiation in neuroblastoma
cells, human ovarian carcinoma cells, and leukemia
cells, among others [13]. However, rapid metabolism
has limited its clinical development due to the need for
constant infusion to maintain bioactive levels [15].
Investigations of other short chain acids, such as 4-
phenylbutyric acid and valproic acid (Figure 1), have
shown them to be effective against similar cancer cell
lines [16,17]. Although 4-phenylbutyric acid’s in vitro
efficacy is low, it was the first HDAC inhibitor to be
evaluated in clinical trials [3]. Valproic acid, a drug
currently used to treat epilepsy and bipolar disorder,
has a significantly longer half-life than sodium
butyrate and has an established clinical record [16].
Depending on the type of HDAC studied, IC50
values for valproic acid have been measured between
0.5 – 2 mM [18,19]. Despite its low potency, valproic
acid was studied as a combination therapy with
retinoic acid in patients with acute myloid leukemia
[20].
Originally isolated from Streptomyces hygroscopicus
as an antifungal antibiotic agent, (R)-Trichostatin A
(TSA) (Figure 1) was found to induce cell differen-
tiation [4,21]. Further studies revealed HDACs to be
its molecular target. TSA, with its ability to bind Znþ2
in a bidentate fashion, not only is one of the most
potent inhibitors of HDAC with an IC50 less than
10 nM, but it also spawned the investigation into the
largest class of HDAC inhibitors — the hydroxamic
acids. Studies with hydroxamic acids and longer chain
fatty acids led to the development of suberoylanilide
hydroxamic acid (SAHA) (Figure 1), which is
currently in phase III clinical trials [3,22]. Crystal-
lographic studies of TSA and SAHA bound to HDLP
show that the hydroxamic acid not only provides
additional binding to the Znþ2 via the N-hydroxyl
group, but the nitrogen and hydroxyl species also serve
as H-bond donors to active-site histidines. Although
SAHA is expected to be introduced on the market in
the near future [23], TSA has had limited clinical
success. TSA is now commercially available in
enantiopure form, but the costly asymmetric synthesis
hampers its pharmaceutical development. An earlier
study with mouse xenographs also showed no
antitumor activity. It was suggested that this could
be due in part to TSA’s poor solubility [24]. There is
also mixed data regarding the toxicity of hydroxamic
acids in general. Multiple animal and clinical studies
on TSA and SAHA have not shown general toxicity or
teratogenicity [25]. However, earlier studies of
hydroxamic acid metabolism show that hydrolysis
can produce hydroxylamine, which is a potential
mutagen [26]. Pharmokinetic studies of TSA have
shown that hydroxamic acids are prone to glucor-
onidation, sulfonation, and reduction to the amide
[26]. Enolization to the S-enantiomer or hydrolysis to
the corresponding carboxylic acid also results in
inactivity. This metabolic instability results in a
relatively short half-life in vivo [28].
The goals of this study are to combine the beneficial
structural features of both short-chain fatty acids and
hydroxamic acids. Short-chain acids have improved
solubility, low toxicity, and are relatively easy to obtain
and derivitize. Hydroxamates provide increased
inhibition via bidentate binding to the Znþ2 and
additional hydrogen bonds. 5-Phenylvaleric acid,
3-benzoylpropanoic acid, 3-benzoylbenzoic acid, and
4-benzoylbenzoic acid were selected as synthetic
starting points not only for their similarity to 4-
phenylbutyric acid, but because they are relatively
inexpensive and commercially available. 4-Phenylbu-
tyric acid derivatives were also developed for
comparison. The hydroxamic acid, N-methyl hydro-
xamate and N,O-dimethyl hydroxamate derivatives of
Figure 1. Structures of known HDAC inhibitors.
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these compounds were synthesized and their inhi-
bition of rat-liver HDAC was investigated. The
methylated hydroxamates were developed as potential
alternatives to hydroxamic acids. It is hypothesized
that these compounds will still bind to the Znþ2 in a
bidentate fashion while potentially reducing the
metabolic concerns. Because the methyl groups
could lead to negative steric interactions and eliminate
key hydrogen bonds, the inhibition of these com-
pounds was compared to the corresponding carboxylic
and hydroxamic acids in this study.
Materials and methods
General
All of the carboxylic acid starting materials were
purchased from Aldrich (Milwaukee, WI) and were
used without further purification. 1H and 13C NMR
spectra were obtained using a 300 MHz Varian
Gemini instrument. FTIR spectra were obtained
using either a Thermo Nicolet Avatar 360 FT-IR ESP
or a MIDAC M series FTIR. Elemental analysis was
performed using a Perkin-Elmer 2400 series II CHN
analyzer. Mass spectroscopy data was obtained using a
Micromass LCT Time-of-Flight Mass Spectrometer
with Electrospray and APCI. Elemental analysis and
mass spectroscopy studies were performed by the
Department of Chemistry’s facilities at the University
of Michigan in Ann Arbor, MI.
General procedure for synthesis of hydroxamates
The desired carboxylic acid (0.1 moles) was added to
150 mL of dry THF in a nitrogen flushed flask. N-
methylmorpholine (0.1 moles) was added and the
solution/mixture was stirred at room temperature
under nitrogen atmosphere for 0.5 h. Isopropyl chlor-
oformate (0.12 moles) was added drop-wise producing
a cloudy solution. This mixture was stirred at room
temperature for 2.5 h before a solution containing the
desired hydroxylamine (0.12 moles) and N-methylmor-
pholine (0.12 moles) in dry acetonitrile was added. The
resulting mixture was stirred overnight. Following
removal of the solvent using rotary evaporation, the
resulting slurry was dissolved in 10% HCl and extracted
three times with ethyl acetate. The combined organic
layers were extracted twice with saturated sodium
carbonate, followed by sodium chloride, and then dried
over anhydrous magnesium sulfate. The solvent was
evaporated to yield a yellowish oil which was chromato-
graphed, using hexane/ethyl acetate mixtures (gradient
chromatography) as eluent, to yield white or off-white
solids or oils as products (Figure 2). Yields ranged from
68% to 80%.
4-Phenylbutyric acid hydroxamate (2). Melting point:
73–778C. 1H NMR (CDCl3): d 1.95 (quintet,
J ¼ 7.5 Hz, 2H), 2.36 (t, J ¼ 7.5 Hz, 2H), 2.66 (t,
J ¼ 7.8 Hz, 2H), 7.18 (distorted triplet, J ¼ 8.1 Hz,
3H), 7.27 (distorted triplet, J ¼ 7.8 Hz, 2H), 9.6
(broad singlet). 13C NMR (CDCl3): d 30.4, 32.34,
35.20, 125.5, 128.01, 128.09, 141.7, 171.5. IR (KBr)
cm21: 3241, 3055, 3029, 2962, 1787, 1710, 1454,
1266, 1107. EA: Found: 66.92% C, 7.31% H, 7.81%
N. Calculated: 67.02%, 7.31% H, 7.82% N.
4-Phenylbutyric acid N-methylhydroxamate (3). 1H
NMR (CDCl3): d 2.0 (quintet, J ¼ 7.2 Hz, 2H),
2.42 (t, J ¼ 7.5 Hz, 2H), 2.68 (t, J ¼ 7.8 Hz, 2H),
3.14 (singlet, 3H), 7.15 (distorted triplet, J ¼ 8.1 Hz,
3H), 7.29 (distorted triplet, J ¼ 7.8 Hz, 2H), 9.5
(broad Singlet). 13C NMR (CDCl3): d 30.84, 31.6,
35.42, 35.77, 125.44, 128.04, 128.1, 141.9, 174.7. IR
(neat) cm21: 3175, 3031, 2939, 2864, 1618, 1490,
1201. EA: Found: 67.90% C, 7.92% H, 6.71%
N. Calculated: 68.37% C, 7.32% H, 7.25% N.
4-Phenylbutyric acid N,O-dimethylhydroxamate (4). 1H
NMR (CDCl3): d 1.97 (quintet, J ¼ 7.5 Hz, 2H),
2.38 (t, J ¼ 7.5 Hz, 2H), 2.63 (t, J ¼ 7.8 Hz, 2H),
3.1 (singlet, 3H), 3.6 (singlet, 3H), 7.17 (distorted
triplet, J ¼ 8.1 Hz, 3H), 7.27 (distorted triplet,
J ¼ 7.8 Hz, 2H). 13C NMR (CDCl3): d 30.85,
32.26, 35.34, 35.86, 60.52, 125.48, 128.04, 128.1,
141.7, 174.6. IR (neat) cm21: 2938, 2868, 1672,
1497, 1387, 1094. MS: [M þ Na]þ ¼ 230.1151.
Calculated: 230.1157.
5-Phenylvaleric acid hydroxamate (6). Melting point:
49–538C. 1H NMR (CDCl3): d 1.66 (quintet,
J ¼ 3 Hz, 4H), 2.48 (t, J ¼ 6 Hz, 2H), 2.59
(t, J ¼ 3 Hz, 2H), 4.2 (broad), 7.2 (distorted triplet,
Figure 2. General synthesisof hydroxamate, N-methylhydrox-
amates, and N,O-dimethylhydroxamates.
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J ¼ 6.6 Hz, 3H), 7.31 (distorted triplet, J ¼ 6.6 Hz,
2H), 9.5 (broad singlet). 13C NMR (CDCl3): d 24.72,
30.41, 32.3, 35.15, 125.48, 128.0, 128.1, 141.72,
171.4. IR (KBr) cm21: 3202, 3030, 2928, 2861,
1618, 1458. MS: [M þ H]þ ¼ 294.1172.
Calculated: 294.1172.
5-Phenylvaleric acid N-methylhydroxamate (7). 1H
NMR (CDCl3): d 1.70 (quintet, J ¼ 3 Hz, 4H),
2.58 (t, J ¼ 6 Hz, 2H), 2.66 (t, J ¼ 3 Hz, 2H), 3.26
(s, 3H), 7.2 (distorted triplet, J ¼ 6.6 Hz, 3H), 7.29
(distorted triplet, J ¼ 6.6 Hz, 2H), 9.5 (broad
singlet). 13C NMR (CDCl3): d 24.28, 30.94, 31.76,
35.4, 35.8, 125.48, 128.04, 128.1, 141.95, 174.4. IR
(neat) cm21: 3190, 3023, 2939, 2871, 1611, 1497,
1459, 1383, 1201. MS: [M þ H]þ ¼ 208.1336.
Calculated: 208.1338.
5-Phenylvaleric acid N,O-dimethylhydroxamate (8). 1H
NMR (CDCl3): d 1.72 (quintet, J ¼ 3 Hz, 4H), 2.50
(t, J ¼ 6 Hz, 2H), 2.62 (t, J ¼ 3 Hz, 2H), 3.16 (s,
3H), 3.72 (s, 3H), 7.2 (distorted triplet, J ¼ 6.6 Hz,
3H), 7.29 (distorted triplet, J ¼ 6.6 Hz, 2H). 13C
NMR (CDCl3): d 24.30, 30.85, 32.26, 35.34, 35.86,
60.52, 125.48, 128.04, 128.1, 141.95, 174.6. IR
(neat) cm21: 3084, 3031, 2939, 2864, 1672, 1452,
1383. EA: Found: 70.55% C, 8.59% H, 5.91%N.
Calculated: 70.56% C, 8.65% H, 6.33% N.
3-Benzoylpropanoic acid hydroxamate (10). Melting
point: 96–988C. 1H NMR (CDCl3): d 2.92 (t,
J ¼ 6.6 Hz, 2H), 3.37 (t, J ¼ 6.6 Hz, 2H), 7.45 (tt,
J ¼ 7.2 Hz, J ¼ 1.2 Hz, 2H), 7.53 (tt, J ¼ 7.5 Hz,
J ¼ 1.2 Hz,1H), 8.0 (dt, J ¼ 6.9 Hz, J ¼ 1.8 Hz,
2H), 9.6 (broad singlet, 1H). 13C NMR (CDCl3): d
25.6, 31.4, 127.7, 128.33, 132.7, 136.3, 172.9, 198.3.
IR (KBr) cm21: 3405, 3055, 2987, 1686, 1627, 1449,
1422, 1267. EA: Found: 62.14% C, 5.76% H, 7.24%
N. Calculated: 62.17% C, 5.74% H, 7.25% N.
3-Benzoylpropanoic acid N-methylhydroxamate (11).
Melting point: 103–1058C. 1H NMR (CDCl3): d
2.85 (t, J ¼ 6.6 Hz, 2H), 3.2 (s, 3H), 3.28 (t,
J ¼ 6.6 Hz, 2H), 7.43 (tt, J ¼ 7.2 Hz, J ¼ 1.2 Hz,
2H), 7.6 (tt, J ¼ 7.5 Hz, J ¼ 1.2 Hz,1H), 8.02 (dt,
J ¼ 6.9 Hz, J ¼ 1.8 Hz, 2H), 9.44 (broad singlet,
1H). 13C NMR (CDCl3): d 25.56, 31.8, 32.52,
127.59 128.3, 132.66, 136.3, 172.8, 198.7. IR (KBr)
cm21: 3144, 2944, 2876, 2718, 1674, 1603, 1508,
1201. EA: Found: 63.65% C, 6.56% H, 6.83%
N. Calculated: 63.76% C, 6.32% H, 6.76% N.
3-Benzoylpropanoic acid N,O-dimethylhydroxamate
(12). 1H NMR (CDCl3): d 2.87 (t, J ¼ 6.6 Hz,
2H), 3.18 (s, 3H), 3.32 (t, J ¼ 6.6 Hz, 2H), 3.753
(s, 3H), 7.43 (tt, J ¼ 7.2 Hz, J ¼ 1.2 Hz, 2H), 7.53
(tt, J ¼ 7.5 Hz, J ¼ 1.2 Hz,1H), 7.98 (dt,
J ¼ 6.9 Hz, J ¼ 1.8 Hz, 2H). 13C NMR (CDCl3): d
25.62, 31.78, 32.52, 60.79, 127.63, 128.13, 132.73,
136.33, 172.85, 198.49. IR (neat) cm21: 3065, 2669,
2940, 2917, 1682, 1661, 1449, 1362, 1242, 1181,
1001. EA: Found: 65.24% C, 6.96% H, 5.39%
N. Calculated: 65.14% C, 6.83% H, 6.33% N.
3-Benzoylbenzoic acid hydroxamate (14). Melting
point: 147–1488C. 1H NMR (CDCl3): d 7.35 (m,
3H), 7.49 (t, J ¼ 7.5 Hz), 7.69 (m, 4H), 7.94 (broad
singlet, 1H), 9.50 (broad, 1H). 13C NMR (CDCl3): d
128.2, 129.4, 129.82, 131.62, 132.38, 136.45, 137.7,
171.4, 196.1. IR (KBr) cm21: 3318, 3059, 2816,
1653, 1622, 1561, 1285. EA: Found: 69.90% C,
4.79% H, 5.87% N. Calculated: 69.70% C, 4.60% H,
5.81% N.
3-Benzoylbenzoic acid N-methylhydroxamate (15).
Melting point: 81–838C. 1H NMR (CDCl3): d 3.25
(s, 3H), 7.40 (m, 3H), 7.53 (t, J ¼ 7.5 Hz), 7.72 (m,
4H), 7.9 (broad singlet, 1H), 9.34 (broad, 1H, OH).
13C NMR (CDCl3): d 36.9, 128.3, 129.32, 129.76,
131.72, 132.6, 136.4, 137.7, 172.1, 195.5. IR (KBr)
cm21: 3117, 3059, 2816, 1667, 1613, 1578, 1323,
1275, 1215. EA: Found: 70.56% C, 5.47% H, 5.42%
N. Calculated: 70.58% C, 5.13% H, 5.49% N.
3-Benzoylbenzoic acid N,O-dimethylhydroxamate (16).
1H NMR (CDCl3): d 3.25 (s, 3H), 3.77 (s, 3H), 7.37
(m, 3H), 7.50 (t, J ¼ 7.5 Hz), 7.67 (m, 4H), 7.90
(broad singlet, 1H). 13C NMR (CDCl3): d 37.8,
61.14, 128.12, 129.27, 129.7, 131.66, 132.58,
136.42, 137.7, 171.09, 195.8, 171.09, 195.8. IR
(neat) cm21: 3067, 2938, 1780, 1723, 1661, 1447,
1279, 1172. MS: [M þ Na]þ ¼ 292.0948.
Calculated: 292.0950.
4-Benzoylbutyric acid hydroxamate (18). Melting point:
115–1188C. 1H NMR (CDCl3): d 2.0 (quintet,
J ¼ 6.9 Hz, 2H), 2.42 (broad triplet, J ¼ 6.9 Hz,
2H), 2.97 (t, J ¼ 7.2 Hz, 2H), 7.37 (t, J ¼ 7.2 Hz,
2H), 7.47 (t, J ¼ 7.5 Hz, 1H), 7.90 (d, J ¼ 7.5 Hz,
2H). 13C NMR (CDCl3): d 18.65, 30.42, 31.58,
127.8, 128.2, 132.63, 136.50, 173.62, 199.7. IR
(KBr) cm21: 3177, 3065, 3027, 2926, 1744, 1707,
1611, 1453. EA: Measured: 63.42% C, 6.43% H,
9.19% N. Calculated: 63.76% C, 6.32%H, 6.76% N.
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4-Benzoylbutyric acid N-methylhydroxamate (19).
Melting point: 89–918C. 1H NMR (CDCl3): d 2.08
(quintet, J ¼ 6.9 Hz, 2H), 2.45 (broad triplet,
J ¼ 6.9 Hz, 2H), 3.05 (t, J ¼ 7.2 Hz, 2H), 3.17 (s,
3H), 7.37 (t, J ¼ 7.2 Hz, 2H), 7.47 (t, J ¼ 7.5 Hz,
1H), 7.90 (d, J ¼ 7.5 Hz, 2H). 13C NMR (CDCl3): d
18.42, 30.60, 31.6, 37.2, 127.7, 128.31, 132.46,
136.7, 173.5, 199.2. IR (KBr) cm21: 3175, 2897,
1672, 1611, 1447, 1181. EA: Found: 65.30% C,
7.19% H, 6.22% N. Calculated: 65.14% C, 6.83% H,
6.33% N.
4-Benzoylbutyric acid N,O-dimethylhydroxamate (20).
1H NMR (CDCl3): d 2.01 (quintet, J ¼ 6.9 Hz, 2H),
2.48 (broad triplet, J ¼ 6.9 Hz, 2H), 3.01 (t,
J ¼ 7.2 Hz, 2H), 3.10 (s, 3H), 3.59 (s, 3H), 7.37 (t,
J ¼ 7.2 Hz, 2H), 7.47 (t, J ¼ 7.5 Hz,1H), 7.90 (d,
J ¼ 7.5 Hz, 2H). 13C NMR (CDCl3): d 18.71, 30.52,
31.78, 37.35, 60.8, 127.7, 128.2, 132.6, 136.47,
173.7, 199.5. IR (neat) cm21: 3061, 2940, 1686, 1449,
1231, 1185, 993. MS: [M þ Na]þ ¼ 258.1112.
Calculated: 258.1106.
HDAC assay
Assay of HDAC activity was modified from the
method of Wegener [29]. The assay is a two-
step reaction. During the first step, HDAC deacety-
lates the e-acetylated lysine residue of the substrate. In
the second step, 4-amino-7-methylcoumarin is
cleaved from the deacetylated substrate using trypsin,
causing a significant increase in fluorescence com-
pared to the acetylated substrate. Assays were run in
triplicate with positive and negative controls in at least
three separate experiments.
The peptide substrate of AC-Arg-Gly-Lys(AC)-
AMC (Bachem, USA; 5 mg) was initially dissolved in
DMSO and diluted in HDAC buffer (15 mM Tris-
HCl [pH 8.1], 250mM EDTA, 250 mM NaCl, 10%
glycerol) to give a 1 mM solution. Rat liver HDAC
(Calbiochem, Germany; 89 U/mL) was diluted in
HDAC buffer. Stock solutions of all inhibitors were
made in DMSO.
Enzyme reactions were prepared by combining
HDAC buffer, the diluted enzyme (3 U/mL), and
10mL of inhibitor stock solutions to achieve a final
concentration of 10% DMSO. Following 5 min of
incubation at 308C, the reaction was initiated by the
addition of substrate (300mM) to bring the total
volume to 100mL. Following a second incubation at
308C for 1 h, 100mL of stop solution was added
(10 mg/mL trypsin in 50 mM Tris-HCl [pH 8.0],
100 mM NaCl, 2mM TSA). After incubation for an
additional 30 min at 308C, the amount of free AMC
was measured by monitoring the fluorescence inten-
sity (EX ¼ 380 nm, EM ¼ 485 nm) using a Jobin
Yvon FluoroMax-3 spectrofluorometer.
Results and discussion
The fatty acids and the synthesized hydroxamate
analogs were tested for their ability to inhibit the
activity of rat-liver HDAC using a fluorescently
labeled, acetylated, tripeptide mimic of the native
acetylated lysine substrate. As 4-phenylbutyric
acid and 5-phenylvaleric acid are reported to be
millimolar-level inhibitors, all compounds were
initially tested at 1 mM. The percent inhibition of
these compounds is reported relative to the activity of
HDAC in the presence of DMSO only (Table I). 4-
Phenylbutyric acid and 5-phenylvaleric acid are
consistent with the IC50 values of 0.64 mM and
1.4 mM previously reported [30]. The percent
inhibition of TSA at 200 nM was also measured and
found to be 70–85% under these conditions. Previous
studies report the IC50 of TSA to be between 2–26
nM [11]. These small discrepancies can be explained
due to differences in the assay method and enzyme
source.
Comparison of the carboxylic acid compounds 1, 5,
9, 13, and 17 to the hydroxamic acids 2, 6, 10, 14, and
18 shows significant improvement in inhibition as
would be expected by the bidentate binding of the
hydroxamate to the Znþ2 cation versus the mono-
dentate binding of the carboxylic acid. The greatest
inhibition was seen with compounds 6 and 18. The
IC50 values were determined for 6 and 18 and were
found to be 5mM and 133 mM respectively (Figure 3).
These values are in line with a previously determined
IC50 value of 1.5mM for 5-benzoylvaleric acid
hydroxamate [31]. Although the values show 6 and
18 to be less effective than other hydroxamates such as
TSA and SAHA, they show increased efficacy when
compared to other derivatives of 4-phenylbutyric acid
and valproic acid [18].
Analysis of the 4-phenylbutyric analogs and the 3-
benzoylpropanoic analogs shows the additional car-
bonyl on chains of equal length to have a small
negative effect on inhibition. This affect is less
significant when comparing chains one carbon longer
in length as seen by comparison of the 5-phenylvaleric
analogs to the 3-benzoylbenzoic and 4-benzoylbutyric
analogs. It was hoped that this would help inhibition
as amide cap groups, such as that found in SAHA,
have proven to be beneficial. Perhaps the shorter chain
lengths in these compounds when compared to SAHA
alter the placement of the carbonyl and negate the
benefit provided by this group.
Crystallographic and modeling studies of TSA and
SAHA in the catalytic core of HDAC predict that
three key H-bonds are formed between the carbonyl
oxygen, the NH and the OH to a tyrosine and two
histidines respectively. The only methylated hydro-
xamate previously reported was an O-methyl, pheny-
lamide derivative of TSA with a five carbon linker
chain. It had an IC50 value greater than 10mM [11]
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while the corresponding hydroxamate had an IC50
value of 0.57mM. Therefore, it was expected that we
would see a drop in inhibition when the N-
methylhydroxamate analogs (3, 7, 11, 15, and 19)
were compared to the hydroxamates (2, 6, 10, 14, and
18) due to loss of one of these key H-bonds. For
compounds 3, 15, and 19, the N-methyl hydroxamates
still provided a benefit over the carboxylic acid binding
groups. A surprising result was the increased
inhibition of 4, 12, and 20 over their N-methyl
counterparts despite the loss of a second H-bond.
This could be explained by increased electron
donating ability of the methoxy group relative to the
hydroxy resulting in tighter binding to the Znþ2
cation. It is unclear why compounds 8 and 16 do not
show this trend. They are, however, on the extremes of
conformational flexibility for this series of compounds
and may have increased steric or hydrophobic
constraints from the two methyl groups within the
active site.
The body of data collected for TSA analogs has
revealed that five to six carbons in the linking region to
be an optimal length for inhibition [3,11]. Hydro-
xamate compounds that contained a benzoyl
cap group also showed an increase in inhibition with
increasing chain length where six intervening methyl-
ene groups were found to be optimal [31]. Previous
studies of other phenyl substituted fatty acids from 4-
phenylbutyric acid through 10-phenyldecanoic acid
however did not show a clear trend of increasing
inhibition with increasing chain length. Our results
also show increased inhibition with increased linker
regions for the hydroxamic acids but not for the
carboxylic acids. As the substituted hydroxamates also
do not show a clear trend in this regard, it appears that
when the key hydrogen bonds afforded by the
hydroxamate are absent, the exact placement of the
Zn binding group in the active site is less critical.
This preliminary investigation of hydroxamic acid
analogs of short-chain fatty acids shows the potential
of combining characteristics of these two inhibitor
types. Although relatively simple in structure, phenyl
or benzoyl substituted fatty acids provide an econ-
omically and synthetically accessible platform for
inhibitors. Modification of the carboxylate moiety to a
hydroxamate provides increased inhibition while
substitution with an N,O-dimethyl hydroxamate
could provide effective inhibitors with longer resi-
dence times in vivo.
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